Aging-related Alterations in mTOR Signaling Promote Platelet Hyperreactivity and Thrombosis.

aging phosphoproteome platelets tandem mass tag thrombosis

Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
05 Jun 2024
Historique:
received: 05 01 2024
revised: 12 04 2024
accepted: 13 05 2024
medline: 8 6 2024
pubmed: 8 6 2024
entrez: 7 6 2024
Statut: aheadofprint

Résumé

Aging is an independent risk factor for the development of cardiovascular, thrombotic and other chronic diseases. However, mechanisms of platelet hyperactivation in aging remain poorly understood. Here, we examine whether and how aging alters intracellular signaling in platelets to support platelet hyperactivity and thrombosis. Quantitative mass spectrometry with tandem mass tag (TMT) labeling systematically measured protein phosphorylation in platelets from healthy aged (>65 years) and young human (<45 years) subjects. The role of platelet mTOR in aging-induced platelet hyperreactivity was assessed using pharmacological mTOR inhibition and a platelet-specific mTOR-deficient mouse model (mTOR Quantitative phosphoproteomics uncovered differential site-specific protein phosphorylation within mTOR, Rho GTPase and MAPK pathways in platelets from aged donors. Western blot confirmed constitutive activation of the mTOR pathway in platelets from both aged humans and mice, which was associated with increased aggregation compared to young controls. Inhibition of mTOR either with Torin 1 in aged humans, or genetic deletion in aged mice, reversed platelet hyperreactivity. In a collagen-epinephrine pulmonary thrombosis model, aged wild-type (mTOR Aging-related changes in mTOR phosphorylation enhance Rac1 and p38 activation, to enhance thromboxane generation, platelet hyperactivity and thrombosis.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Aging is an independent risk factor for the development of cardiovascular, thrombotic and other chronic diseases. However, mechanisms of platelet hyperactivation in aging remain poorly understood. Here, we examine whether and how aging alters intracellular signaling in platelets to support platelet hyperactivity and thrombosis.
METHODS METHODS
Quantitative mass spectrometry with tandem mass tag (TMT) labeling systematically measured protein phosphorylation in platelets from healthy aged (>65 years) and young human (<45 years) subjects. The role of platelet mTOR in aging-induced platelet hyperreactivity was assessed using pharmacological mTOR inhibition and a platelet-specific mTOR-deficient mouse model (mTOR
RESULTS RESULTS
Quantitative phosphoproteomics uncovered differential site-specific protein phosphorylation within mTOR, Rho GTPase and MAPK pathways in platelets from aged donors. Western blot confirmed constitutive activation of the mTOR pathway in platelets from both aged humans and mice, which was associated with increased aggregation compared to young controls. Inhibition of mTOR either with Torin 1 in aged humans, or genetic deletion in aged mice, reversed platelet hyperreactivity. In a collagen-epinephrine pulmonary thrombosis model, aged wild-type (mTOR
CONCLUSION CONCLUSIONS
Aging-related changes in mTOR phosphorylation enhance Rac1 and p38 activation, to enhance thromboxane generation, platelet hyperactivity and thrombosis.

Identifiants

pubmed: 38849085
pii: S1538-7836(24)00317-9
doi: 10.1016/j.jtha.2024.05.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Irina Portier (I)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.

Bhanu Kanth Manne (BK)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.

Yasuhiro Kosaka (Y)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.

Neal D Tolley (ND)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.

Frederik Denorme (F)

University of Utah Molecular Medicine Program, Salt Lake City, Utah; Division of Vascular Neurology, Department of Neurology, University of Utah, Salt Lake City, Utah.

Özgün Babur (Ö)

Department of Computer Science, University of Massachusetts Boston, Boston, Massachusetts.

Ashok P Reddy (AP)

Proteomics Shared Resource, Oregon Health & Science University, Portland, Oregon.

Phillip A Wilmarth (PA)

Proteomics Shared Resource, Oregon Health & Science University, Portland, Oregon.

Joseph E Aslan (JE)

Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.

Andrew S Weyrich (AS)

Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.

Matthew T Rondina (MT)

University of Utah Molecular Medicine Program, Salt Lake City, Utah; Division of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, Utah; George E. Wahlen VAMC Department of Internal Medicine and the Geriatric Research, Education and Clinical Center (GRECC), Salt Lake City, Utah.

Robert A Campbell (RA)

University of Utah Molecular Medicine Program, Salt Lake City, Utah; Division of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, Utah. Electronic address: rcampbell@u2m2.utah.edu.

Classifications MeSH